Contact Us
Search
Close this search box.

Team

Meet our dedicated and inspiring leadership team.

Owen Roberts, CFA

Chief Executive Officer

Holly Bilton, PhD

Associate Director, Business Development
Associate Director, Business Development

Meenalochani Sivasubramain, PhD

Associate Director, Research and
Project Management
Associate Director, Research and Project Management

Zainab Ahmad, PhD

Research Manager

Ruth Organ, CPA

Sr. Director, Controller, Finance
and Administration

Supriya Mehra, CPA

Manager, Finance and Administration

Board of directors

CPDC is governed by an independent Board of Directors. Board members represent all key sectors associated with the CPDC. The Board of Directors works with the CEO and CPDC executive team to shape the CPDC’s future direction and success.

John Thornback

Chair of the CPDC Board of Directors

Lana Janes

Cofounder, Chief Operating Officer
Abdera Therapeutics

Damian Lamb

Managing Director,
Genesys Capital

Peter Pattison

President,
Interventional Oncology,
Boston Scientific

Owen Roberts

CEO, CPDC

Sheila Singh

Pediatric Neurosurgeon,
McMaster Children’s Hospital

John Valliant

CEO,
Fusion Pharmaceuticals

Annick Van den Abbeele

Founding Director,
Center for Biomedical Imaging in Oncology (CBIO),
 Dana-Farber Cancer Institute

Bettina Hamelin

President and CEO,
Ontario Genomics

Jean-Claude Provost

Interim Chief Medical Officer,
Lantheus

Christopher Kelly

Deputy Director,
Networks of Centres of Excellence

Gay Yuyitung

Vice-Chair of the CPDC Board of
Directors

Karen Gulenchyn

Nuclear Medicine Physician,
Hamilton Hospitals and Cambridge
Memorial Hospital
Suite 111
175 Longwood Rd. S.
Hamilton, Ontario, Canada, L8P 0A1

info@cpdc.ca

OUR PARTNERS

Suite 111
175 Longwood Road. S.
Hamilton, Ontario, Canada, L8P 0A1

info@cpdc.ca

Our Partners

© 2021 Centre for Probe Development and Commercialization. All rights reserved. Accessibility
Follow us on

Owen Roberts, CFA

Chief Executive Officer
Owen Roberts joined the Centre for Probe Development and (CPDC) in October 2022 as Chief Executive Officer, bringing over 20 years of biotech executive experience to his role at CPDC.

A serial biotech entrepreneur, Owen was most recently the founder and CEO of Nobelex Biotech Inc., a Canadian biotech contract research organization focused on discovering and developing antibiotics to treat bacterial infections caused by drug-resistant bacteria. In addition to leading Nobelex since 2014, Owen also held part-time senior management roles with Meta Inc. (as CFO from 2015-2016) and M4K Pharma (as CEO from 2017 to 2020).

Prior to founding Nobelex in 2014, Owen was a co-founder of Affinium Pharmaceuticals, a privately held venture funded, clinical stage, antibiotic company. At Affinium, Owen held the position of CFO and led the company’s finance and business development until the successful sale of Affinium’s antibiotic programs to Debiopharm International, S.A. in February 2014. Prior to Affinium, in 1998, Owen helped create Borealis Biosciences, one of two companies which would merge to form Affinium in 2000. Prior to entering biotech, Owen was a financial executive at the Canadian subsidiaries of major US financial institutions.

Owen is a graduate of McGill University and is also a Chartered Financial Analyst.
Owen Roberts joined the Centre for Probe Development and (CPDC) in October 2022 as Chief Executive Officer, bringing over 20 years of biotech executive experience to his role at CPDC.

A serial biotech entrepreneur, Owen was most recently the founder and CEO of Nobelex Biotech Inc., a Canadian biotech contract research organization focused on discovering and developing antibiotics to treat bacterial infections caused by drug-resistant bacteria. In addition to leading Nobelex since 2014, Owen also held part-time senior management roles with Meta Inc. (as CFO from 2015-2016) and M4K Pharma (as CEO from 2017 to 2020).

Prior to founding Nobelex in 2014, Owen was a co-founder of Affinium Pharmaceuticals, a privately held venture funded, clinical stage, antibiotic company. At Affinium, Owen held the position of CFO and led the company’s finance and business development until the successful sale of Affinium’s antibiotic programs to Debiopharm International, S.A. in February 2014. Prior to Affinium, in 1998, Owen helped create Borealis Biosciences, one of two companies which would merge to form Affinium in 2000. Prior to entering biotech, Owen was a financial executive at the Canadian subsidiaries of major US financial institutions.

Owen is a graduate of McGill University and is also a Chartered Financial Analyst.
Linkedin-in

Holly Bilton, PhD

Associate director, research & program management
Holly Bilton joined CPDC in 2019 as the Research Manager and transitioned into her current role of Associate Director, Research & Program Management in October 2022. In her current role, Dr. Bilton manages the research programs at CPDC, ranging from early stage discovery, development, and clinical programs.

Holly has over 8 years’ experience in radiopharmaceutical development. Prior to joining CPDC, Holly obtained her PhD from McMaster University under Dr. John Valliant, focusing on the discovery and development of radiopharmaceuticals and multimodal imaging probes.
Holly Bilton joined CPDC in 2019 as the Research Manager and transitioned into her current role of Associate Director, Research & Program Management in October 2022. In her current role, Dr. Bilton manages the research programs at CPDC, ranging from early stage discovery, development, and clinical programs.

Holly has over 8 years’ experience in radiopharmaceutical development. Prior to joining CPDC, Holly obtained her PhD from McMaster University under Dr. John Valliant, focusing on the discovery and development of radiopharmaceuticals and multimodal imaging probes.
Linkedin-in

Meenalochani Sivasubramanian, PhD

Associate director, research & program management
Meenalochani Sivasubramanian joined CPDC in
December 2022 as the Associate Director, Research &
Project Management. In her current role, Dr.
Sivasubramanian manages the PSMA 1007 Clinical
programs at CPDC.

Dr. Sivasubramanian has a PhD in Neuroscience from
the National University of Singapore and over 8 years
of experience as a postdoctoral fellow working on
various neurodegenerative and neuropsychiatric
disorders of the brain, elucidating pathophysiologic
mechanisms and potential treatment strategies for
drug addictions, schizophrenia, Huntington Disease
and Parkinson’s disease. Prior to joining here Meena
worked as a Program Manager managing the
operations of the Slaight Family Centre for Advanced
MRI at UHN.
Meenalochani Sivasubramanian joined CPDC in December 2022 as the Associate Director, Research & Project Management. In her current role, Dr. Sivasubramanian manages the PSMA 1007 Clinical programs at CPDC.

Dr. Sivasubramanian has a PhD in Neuroscience from the National University of Singapore and over 8 years of experience as a postdoctoral fellow working on various neurodegenerative and neuropsychiatric disorders of the brain, elucidating pathophysiologic mechanisms and potential treatment strategies for drug addictions, schizophrenia, Huntington Disease and Parkinson’s disease. Prior to joining here Meena worked as a Program Manager managing the operations of the Slaight Family Centre for Advanced MRI at UHN.
Linkedin-in

Zainab Ahmad, PhD

Research Manager
Zainab Ahmad joined CPDC in December 2022 as the
Research Manager. In her current role, Dr. Ahmad
manages the discovery and development research
programs at CPDC.

Zainab has over 6 years of experience in the
development of radiopharmaceuticals having
completed her PhD at McMaster University under Dr.
John Valliant focusing on the discovery and
development of small molecule- and
nanoparticle-based radiopharmaceuticals. Prior to
this, Zainab worked as a Regulatory Consultant at a
chemicals-focused consultancy firm.
Zainab Ahmad joined CPDC in December 2022 as the Research Manager. In her current role, Dr. Ahmad manages the discovery and development research programs at CPDC.

Zainab has over 6 years of experience in the development of radiopharmaceuticals having completed her PhD at McMaster University under Dr. John Valliant focusing on the discovery and development of small molecule- and nanoparticle-based radiopharmaceuticals. Prior to this, Zainab worked as a Regulatory Consultant at a chemicals-focused consultancy firm.
Linkedin-in

Ruth Organ, CPA

Sr. Director, Controller, Finance and Administration

Ruth Organ joined CPDC in 2023 as the Sr. Director, Controller, Finance and Administration. Ruth brings over 20 years of experience in strategic financial leadership roles across Canada from various industries, including communications, advertising & publishing, manufacturing and construction. Ruth has led diverse domestic and global teams in finance, accounting and regulatory, and multi year, company wide transformational projects and initiatives.

In her current role Ruth is responsible for the finance operations, HR, IT and administrative initiates as well as managing the financial aspects of various grant programs.

Ruth is a Chartered Professional Accountant and holds her undergraduate degree from University of Waterloo.

Holly Bilton joined CPDC in 2019 as the Research Manager and transitioned into her current role of Associate Director, Research & Program Management in October 2022. In her current role, Dr. Bilton manages the research programs at CPDC, ranging from early stage discovery, development, and clinical programs.

Holly has over 8 years’ experience in radiopharmaceutical development. Prior to joining CPDC, Holly obtained her PhD from McMaster University under Dr. John Valliant, focusing on the discovery and development of radiopharmaceuticals and multimodal imaging probes.

Supriya Mehra, CPA

Manager, Finance and Administration
Supriya Mehra joined CPDC in 2023 as the Manager, Finance and Administration. In her current role, Supriya is responsible for CPDC’s key financial and accounting activities, focusing on Accounts Receivable, Accounts Payables processes along with administrative initiates. Supriya brings over 15 years of experience in Accounting and Financial Planning and Analysis. Her diverse background includes experience in transportation, manufacturing, and banking industry.

Supriya is a Chartered Professional Accountant and holds her undergraduate degree from Toronto Metropolitan University.
Supriya Mehra joined CPDC in 2023 as the Manager, Finance and Administration. In her current role, Supriya is responsible for CPDC’s key financial and accounting activities, focusing on Accounts Receivable, Accounts Payables processes along with administrative initiates. Supriya brings over 15 years of experience in Accounting and Financial Planning and Analysis. Her diverse background includes experience in transportation, manufacturing, and banking industry.

Supriya is a Chartered Professional Accountant and holds her undergraduate degree from Toronto Metropolitan University.